With this regard, a phase 1 study assesses the combination with a checkpoint inhibitor (NCT03330405) [56], whereas, a phase II study exploring talazoparib activity in advanced cancers with PTEN mutations or PTEN loss and HRD defect (NCT02286687) [57]. This evidence concerns the gene PTEN and cancer.